Press coverage about Retrophin (NASDAQ:RTRX) has been trending somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Retrophin earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 47.7972109822025 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
A number of research analysts recently weighed in on RTRX shares. BidaskClub downgraded shares of Retrophin from a “buy” rating to a “hold” rating in a research report on Saturday, December 30th. ValuEngine upgraded shares of Retrophin from a “sell” rating to a “hold” rating in a research report on Monday, April 9th. Zacks Investment Research downgraded shares of Retrophin from a “hold” rating to a “sell” rating in a research report on Thursday, January 11th. Finally, BMO Capital Markets lowered their price objective on shares of Retrophin from $44.00 to $43.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $43.00.
Shares of Retrophin stock opened at $26.89 on Tuesday. The company has a market cap of $1,083.76, a P/E ratio of -17.93 and a beta of 1.05. Retrophin has a twelve month low of $15.55 and a twelve month high of $28.25. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.74 and a current ratio of 3.80.
Retrophin (NASDAQ:RTRX) last issued its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.20). Retrophin had a negative net margin of 38.55% and a negative return on equity of 13.98%. The company had revenue of $42.18 million for the quarter, compared to the consensus estimate of $42.20 million. research analysts anticipate that Retrophin will post -1.6 earnings per share for the current fiscal year.
WARNING: This piece of content was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/17/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-retrophin-rtrx-share-price.html.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.